METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung C
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
| (NASDAQ: NVCR) | Delayed: 13.11 -1.06 (7.48%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $14.17 | 52 Week High | $28.95 | |||
| Open | $12.60 | 52 Week Low | $5.95 | |||
| Day High | $13.85 | P/E | N/A | |||
| Day Low | $11.85 | EPS | $0.00 | |||
| Volume | 5,955,757 | |||||
